The European Union has long been a source of both classical liberal ideas and expansive government regulation. Today, the EU is increasingly exporting its regulatory model beyond its borders—including policies that threaten free speech online. In a new column in RealClearMarkets, Market Institute Senior Fellow Norm Singleton examines how the Read more…
A new column by The Market Institute President Charles Sauer published in RealClearMarkets examines how outdated tax policy is quietly worsening America’s housing affordability crisis — and how a simple reform could help free up supply and restore the American dream of homeownership. As Sauer explains, owning property has long Read more…
The Market Institute and the Center for a Free Economy (CFE) led a coalition of free-market leaders and organizations urging congressional leadership to pass the More Homes on the Market Act (H.R. 1340 / S. 3332)—a bipartisan reform designed to increase housing supply and improve affordability for American families. In Read more…
The intersection of antitrust enforcement and free speech is once again at the center of a growing policy debate in Washington. In a new RealClearMarkets column, Market Institute President Charles Sauer examines the Federal Trade Commission’s investigation into NewsGuard — and explains why the case represents a troubling expansion of Read more…
In a recent column for RealClearMarkets, Charles Sauer, President of The Market Institute, argues that while Lina Khan may be gone from the Federal Trade Commission, the politicization of antitrust enforcement remains very much alive. For years, free-market advocates criticized former FTC Chair Lina Khan for using antitrust and consumer Read more…
Healthcare is intensely personal, especially when devastating diagnoses arrive. Yet too often, a system weighed down by regulation and bureaucracy compounds that pain, forcing patients and families to navigate life-altering decisions without the support or flexibility they need. In a recent piece published on The Capitalist Substack, Market Institute President Read more…
The Market Institute joined dozens of free-market, taxpayer, and innovation-focused organizations in a February 12 coalition letter to Congress opposing efforts to codify a Most-Favored-Nation (MFN) prescription drug pricing model into law. In the letter, the coalition warned that MFN would not solve the real problem of foreign price controls. Read more…
In a recent column for RealClearMarkets, Market Institute Senior Fellow Norm Singleton examines how a well-intentioned federal program has morphed into a major source of wasteful healthcare spending and industry consolidation. Total healthcare spending is projected to reach nearly $6 trillion this year, with more than $2 trillion coming from Read more…
In a recent article for RealClearHealth, Market Institute President Charles Sauer warns that the Trump administration’s new TrumpRx initiative may deliver lower drug prices in the short run—but at the cost of future medical innovation. Sauer explains that while the goal of lowering pharmaceutical prices is laudable, the method matters. Read more…
In a new RealClearMarkets op-ed, Market Institute Senior Fellow Norm Singleton explains why the Trump Administration’s clash with the European Union over the Digital Services Act (DSA) is really a fight over free speech—especially for American users and companies. Singleton writes that critics, including progressive advocacy groups, have framed the Read more…